Now, a comprehensive critical review published in Molecular Biology Reports by Tianshun Xu, Yaoyang Shen, and colleagues at Ningbo University’s Health Science Center has taken stock of the entire toolbox that scientists use to measure how well human cells perform this vital repair job. The review, led by corresponding authors Geng Wang and Na Li, systematically compares the biochemical, cellular, and genome-wide methods currently available for functional NER analysis, examining what each technique actually measures, how it works, and where its blind spots lie. In doing so, it offers researchers a kind of field guide to an area of biology that has grown fragmented across decades of methodological innovation, and it arrives at a deceptively simple conclusion: no single assay tells the whole story.

To appreciate why measuring NER is so tricky, it helps to understand what the pathway actually does. NER operates through two intertwined branches. Global-genome NER, abbreviated GG-NER, patrols the entire genome, scanning for distortions caused by lesions such as the cyclobutane pyrimidine dimers and pyrimidine (6-4) pyrimidinone photoproducts generated by ultraviolet light. In this surveillance mode, the XPC-RAD23B complex, often assisted by the UV-damaged DNA-binding protein complex, serves as the primary damage sensor. The second branch, transcription-coupled NER, is triggered when RNA polymerase II stalls at a lesion blocking its progress along a gene. Stalled transcription is itself the alarm bell, recruiting factors such as CSB, CSA, and UVSSA that hand the problem over to the shared repair machinery. Both branches converge on a common core: the transcription factor IIH, with its XPB and XPD helicase subunits, verifies the damage and opens the DNA, XPA and RPA help position the incision nucleases XPF-ERCC1 and XPG, and the damaged stretch is cut out as a short oligonucleotide roughly 24 to 32 nucleotides long. The resulting gap is filled by repair synthesis and sealed by ligation.

Because the pathway unfolds in discrete stages, from damage recognition through dual incision, gap filling, and ligation, different assays capture different snapshots of the process. The Ningbo review organizes the field around exactly this principle, grouping methods by the endpoint they interrogate: excision-product formation, repair-associated DNA synthesis, transcriptional or reporter gene-expression recovery, lesion removal inferred from restored DNA amplifiability, and genome-wide mapping of damage and excision events. Each category carries its own technical logic, its own strengths, and its own interpretive caveats, and the review’s central message is that assay selection must be guided by the specific research question at hand, with complementary readouts providing the most complete picture of NER function.

At the biochemical end of the spectrum sit the in vitro excision assays, which trace their lineage to the pioneering work of Aziz Sancar’s laboratory and others who reconstituted human NER in cell-free extracts in the late 1980s and early 1990s. In these systems, damaged plasmid DNA is incubated with cell extracts or purified protein fractions, and the dual-incision products, the small excised oligonucleotides carrying the lesion, are detected by gel electrophoresis or immunological methods. The approach offers exquisite mechanistic resolution: researchers can pinpoint exactly which protein factors are required for each step, as demonstrated in landmark studies that defined the minimal set of human factors needed to reconstitute dual incision. Recent structural biology has pushed this mechanistic understanding even further, with cryo-electron microscopy revealing the pre-incision complexes and the scanning-to-incision switch in TFIIH-XPG that licenses repair. Yet the review is careful to note the limitations of cell-free systems. Extract-based assays strip away the chromatin context in which repair actually occurs in living cells, and studies going back decades have shown that NER is suppressed in reconstituted nucleosomes, meaning that what works beautifully in a test tube may not reflect the chromatin-wrapped reality of the nucleus.

Moving into living cells, the review highlights the classic unscheduled DNA synthesis assay, a technique with roots stretching back to 1964, when Rasmussen and Painter first reported evidence of DNA repair in cultured mammalian cells. Because repair synthesis inserts new nucleotides outside the normal S phase of the cell cycle, it was dubbed unscheduled, and measuring this incorporation, originally with radioactive thymidine and later with the click-chemistry-compatible analog EdU, became the gold-standard functional readout of global-genome NER for decades. The assay remains clinically relevant: it has been used for prenatal diagnosis of xeroderma pigmentosum, the devastating hereditary disorder in which NER defects cause extreme sun sensitivity and a thousands-fold elevated skin cancer risk, and for complementation analysis of patient cells. Modern refinements, including tyramide signal amplification, have made the assay non-radioactive and sensitive enough for single-cell quantification, and parallel measurements of recovery of RNA synthesis provide the complementary readout for transcription-coupled repair, which is the branch specifically defective in Cockayne syndrome and UV-sensitive syndrome.

Perhaps the most versatile family of cellular assays is host cell reactivation, or HCR, in which a reporter plasmid is deliberately damaged in vitro, for example by UV irradiation or treatment with the cigarette-smoke carcinogen benzo[a]pyrene diol epoxide, and then transfected into the cells under study. If the cells’ NER machinery repairs the plasmid, the reporter gene, historically chloramphenicol acetyltransferase and now typically luciferase or fluorescent proteins, switches back on, and the level of expression becomes a proxy for repair capacity. The elegance of the method lies in its scalability and its epidemiological reach: modified HCR assays have been used to measure DNA repair capacity in peripheral blood lymphocytes from large cohorts, revealing associations between reduced repair capacity and elevated risk of skin, lung, head and neck, and bladder cancers. The latest evolution, fluorescence multiplexed HCR, or FM-HCR, deploys barcoded reporter plasmids carrying different types of damage, each tagged with a distinct fluorescent protein, allowing simultaneous quantification of repair across multiple lesion types and multiple pathways in a single sample by flow cytometry. Recent large-scale applications have measured inter-individual variation in DNA repair capacity across healthy populations, opening the door to personalized assessments of genome maintenance.

The most technologically ambitious methods in the review are the genome-wide approaches, chief among them excision repair sequencing, or XR-seq, developed in Sancar’s laboratory. Rather than measuring repair indirectly, XR-seq captures the actual excised oligonucleotides that NER releases, maps them back to the reference genome by next-generation sequencing, and thereby produces single-nucleotide-resolution maps of where repair happened across the entire genome. The technique has generated striking biological insights: repair is faster in transcribed genes than in silent regions, it is modulated by chromatin state, it follows circadian rhythms in mouse tissues, and it varies systematically across the three-dimensional organization of the genome, as shown in recent work mapping the repair of aflatoxin-induced and cisplatin-induced damage. Complementary damage-mapping methods such as Damage-seq and high-sensitivity variants locate the lesions themselves, so that comparing damage maps with excision maps reveals repair kinetics directly. These approaches have even been extended beyond humans, illuminating repair patterns in plants, yeast, and bacteria, and connecting transcription-coupled repair to the Mfd translocase in E. coli.

Why does all this methodological scrutiny matter beyond the laboratory? The review emphasizes that NER sits at a fascinating double-edged intersection with cancer. On one hand, robust NER protects normal cells from mutagenesis, and epidemiological studies have linked weaker repair phenotypes to higher cancer risk. On the other hand, cancer cells can co-opt elevated NER activity to survive the DNA-damaging chemotherapy drugs that oncologists deploy against them. Cisplatin adducts and other bulky lesions are themselves NER substrates, so tumors with high repair capacity can shrug off treatment. This has fueled a therapeutic strategy of NER inhibition: the review’s authors themselves have previously shown that triptolide, a natural product, enhances carboplatin-induced apoptosis in melanoma by suppressing NER activity. Accurate, well-matched assays are therefore essential not only for understanding basic biology but also for identifying which tumors might respond to such combination therapies and for monitoring how interventions actually change repair function in cells.

The review’s final verdict is a call for methodological humility and deliberate design. Because each assay interrogates a distinct stage or consequence of NER, a positive result in one assay cannot be automatically generalized to the whole pathway, and apparent discrepancies between studies may simply reflect different endpoints rather than conflicting biology. Biochemical assays offer mechanistic precision but lack cellular context; cellular reporter assays capture functional outcomes but can be influenced by transcription, replication, and toxicity; genome-wide maps deliver unprecedented resolution but demand substantial sequencing resources and computational expertise. The authors argue that researchers should choose their tools to match their questions and, wherever possible, layer complementary readouts, for example pairing an excision assay with a repair-synthesis measurement or a genome-wide map with a functional reporter, to build a comprehensive assessment of NER capability. As DNA repair biology moves from correlation toward causation in cancer prevention, diagnosis, and treatment, that disciplined, multi-angle approach may prove to be the review’s most enduring contribution.

Subject of Research: Functional methods for assessing nucleotide excision repair capability in human cells

Article Title: Assessment and detection of nucleotide excision repair capability in human cells: a critical review of current functional methods

Article References: Xu, T., Shen, Y., Dai, X., Shao, Y., Zhang, Y., Zhang, Y., Wang, G., & Li, N. (2026). Assessment and detection of nucleotide excision repair capability in human cells: a critical review of current functional methods. Molecular Biology Reports, 53(1), Article 1635. https://doi.org/10.1007/s11033-026-12816-5

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12816-5

Keywords: nucleotide excision repair, DNA damage, DNA repair assays, host cell reactivation, unscheduled DNA synthesis, XR-seq, xeroderma pigmentosum, transcription-coupled repair, genome stability, cancer therapy resistance, TFIIH, functional genomics

The research, led by Chenxi Li, Yingying Qin and Yajuan Yang of Shandong University and collaborating institutions in China, focused on what happens when mouse primordial germ cells lose RAD54 like, or RAD54L. The team found that without this factor, the cells proliferate poorly, leaving an insufficient pool of germ cells and ultimately impairing fertility. The defect traces back to a specific molecular hazard: the accumulation of topoisomerase I cleavage complexes, abbreviated TOP1ccs, which are among the most common and most dangerous lesions that arise during DNA replication.

To appreciate why TOP1ccs matter, it helps to understand what topoisomerase I normally does. As the two strands of the double helix are prised apart for copying, the DNA ahead of the replication machinery becomes overwound, like a rope twisted too tightly. Topoisomerase I relieves this torsional stress by nicking one strand of the DNA, allowing it to swivel freely, and then sealing the break again. The enzyme normally completes this cut-and-paste cycle in a fraction of a second. Occasionally, however, the enzyme becomes trapped mid-cycle, covalently bonded to the DNA at the nick it just created. That trapped enzyme-DNA adduct is the TOP1 cleavage complex, and if it is not removed promptly, the approaching replication fork collides with it, converting a transient intermediate into a double-strand break and stalling DNA synthesis.

Cells possess dedicated machinery to clear these protein-DNA adducts, and the new study adds a surprising player to that list. The researchers showed that RAD54L promotes the degradation of TOP1ccs through the ubiquitin-proteasome pathway, the cellular recycling system that tags unwanted proteins with chains of ubiquitin and delivers them to the proteasome for destruction. The key to this activity lies in a partnership between RAD54L and tripartite motif-containing protein 21, or TRIM21, which the authors identify as a newly recognized E3 ubiquitin ligase responsible for clearing TOP1ccs. E3 ligases are the enzymes that confer specificity on the ubiquitin system, deciding which targets get marked for degradation. In this case, TRIM21 appears to be the enzyme that flags trapped topoisomerase I for removal.

The mechanistic twist is that RAD54L does not itself ligate ubiquitin. Instead, it interacts with TRIM21 and stabilizes the protein, keeping sufficient TRIM21 available to do its clearing work. When RAD54L is absent, TRIM21 is not maintained properly, TOP1ccs accumulate, and the resulting DNA damage escalates. In RAD54L-deficient primordial germ cells, this cascade of events exacerbates DNA damage, undermines proliferation and erodes the reproductive reserve. The finding reframes RAD54L, historically viewed as a homologous recombination factor that helps search for and invade homologous DNA templates during double-strand break repair, as also acting upstream of repair, at the stage of removing the lesions that would otherwise create breaks in the first place.

Primordial germ cells are an especially revealing setting for this kind of analysis. These cells undergo rapid mitotic divisions during embryonic development, and their genome must be transmitted faithfully across generations. High levels of replication, combined with the metabolic demands of a growing embryo, make TOP1ccs a constant threat. The DNA damage response mechanisms that protect somatic cells have been studied extensively, but the regulatory networks that safeguard the germline during this early mitotic phase have remained largely unexplored. By showing that a defect in a single DNA damage response factor can compromise the founding population of the germline, the study connects genome maintenance at the molecular level to fertility at the organismal level.

The experimental logic of the work follows a path familiar to genome stability researchers but with distinctive results. Mice lacking RAD54L in their germ cells show proliferation defects in the primordial germ cell population. The DNA damage observed in these cells is not random; it is specifically tied to TOP1cc accumulation, which means the damage is preventable if the trapped complexes are cleared. The demonstration that RAD54L stabilizes TRIM21 provides a coherent causal chain: loss of RAD54L destabilizes the E3 ligase, the ligase can no longer ubiquitinate trapped topoisomerase I efficiently, the adducts persist, replication forks collide with them, and DNA damage mounts until cells falter or die.

The discovery also resonates with a broader and clinically important theme in cancer medicine. Drugs called topoisomerase I poisons, including camptothecin and its clinical derivatives irinotecan and topotecan, work precisely by stabilizing the TOP1 cleavage complex, trapping the enzyme on DNA and forcing tumor cells into lethal collisions between replication forks and the drug-stabilized adducts. Understanding how healthy cells, and particularly vulnerable populations like germ cells, clear TOP1ccs has implications for how such treatments affect fertility and for how resistance to these drugs emerges. A pathway involving RAD54L and TRIM21 that governs the lifespan of TOP1ccs could, in principle, influence both the toxicity and the efficacy of these widely used chemotherapeutics, although the new study addresses physiology rather than treatment outcomes.

TRIM21 itself carries an interesting scientific history. Long studied in immunology as an antibody receptor inside cells, it has more recently been appreciated as a versatile quality-control factor that recognizes and ubiquitinates a range of intracellular targets. Its identification here as the E3 ligase for TOP1cc clearance in germ cells extends that repertoire into genome maintenance and adds a new dimension to how the ubiquitin system participates in the DNA damage response. The RAD54L-TRIM21 axis suggests that repair factors may do more than mend breaks after they occur; some may actively manage the burden of endogenous lesions so that breaks are less likely to arise at all.

For the field of reproductive biology, the study fills in a piece of a larger puzzle: how the mitotic phase of gametogenesis, before meiosis begins, is protected against the wear and tear of rapid proliferation. The authors frame their results as extending understanding of the regulatory mechanisms that safeguard genome integrity during this process, and the practical significance is clear. A diminished primordial germ cell pool is a diminished reproductive reserve, and the work points to TOP1cc accumulation as one preventable driver of that loss. As with any mouse study, translating the findings to human fertility will require further work, but the core machinery of topoisomerase I, the ubiquitin-proteasome system and the DNA damage response is conserved across mammals, making the pathway a plausible target for future investigations into reproductive health and the side effects of topoisomerase-targeting therapies.

Subject of Research: The role of RAD54L and TRIM21 in clearing topoisomerase I cleavage complexes to maintain genome stability in primordial germ cells

Article Title: RAD54L counteracts topoisomerase I cleavage complexes by stabilizing E3 ligase TRIM21 to maintain genome stability

Article References: Li, C., Wang, S., Xu, W., Kong, Z., Wen, C., Zhao, S., Cao, L., Chen, Z.-J., Zhao, S., Qin, Y., & Yang, Y. (2026). RAD54L counteracts topoisomerase I cleavage complexes by stabilizing E3 ligase TRIM21 to maintain genome stability. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06458-w

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06458-w

Keywords: RAD54L, TRIM21, topoisomerase I cleavage complexes, primordial germ cells, genome stability, DNA damage response, ubiquitin-proteasome pathway, replication stress, fertility, gametogenesis, E3 ubiquitin ligase, DNA repair

The pivotal event in this decision is DNA end resection, the enzymatic trimming of the 5-prime strands at the break to generate single-stranded DNA tails. If resection proceeds, the cell is effectively committed to homologous recombination, because the single-stranded overhangs become coated with the RPA protein and later with RAD51, which searches for homologous sequence on the sister chromatid. If resection is blocked, the ends remain available for the Ku70-Ku80 heterodimer, which recruits the DNA-dependent protein kinase catalytic subunit and the ligase complex that carries out classical non-homologous end joining. Resection is therefore not merely a step in one repair route; it is the molecular switch that determines which route is taken, and its regulation is correspondingly elaborate.

Resection unfolds in two phases. Short-range processing is initiated by the MRE11-RAD50-NBS1 complex, known as MRN, whose nuclease activity is stimulated by the phosphorylated cofactor CtIP. MRN makes an internal incision near the break and removes the blocking Ku protein, a step that single-molecule imaging studies have illuminated in striking detail. Long-range resection then extends the single-stranded tracts over thousands of nucleotides through two principal routes: one driven by the nuclease EXO1, and the other by the helicase-nuclease pair BLM or WRN working with DNA2. These pathways, first defined in budding yeast through the Sgs1-Dna2 and Exo1 systems, are conserved in human cells, where the RecQ helicases cooperate with DNA2 to process breaks and stalled replication forks alike.

Standing athwart this machinery is a famous antagonism between two tumor-suppressive and genome-protective forces: the BRCA1-BARD1 complex and the 53BP1 axis. 53BP1 is recruited to breaks by marks laid down by the RNF8 and RNF168 ubiquitin ligases, and it recognizes dimethylated histone H4 lysine 20 together with ubiquitinated H2A lysine 15 on damaged nucleosomes. Once bound, 53BP1 recruits RIF1 and the shieldin complex, which protect DNA ends and actively counteract resection, in part through CST-Pol-alpha-primase-mediated fill-in synthesis that restores paired ends. Bunting and colleagues showed in 2010 that loss of 53BP1 restores homologous recombination in BRCA1-deficient cells, establishing that these two pathways act in direct opposition at the same breaks.

Recent biochemical work has sharpened the picture of how BRCA1-BARD1 wins this contest in the appropriate cellular context. Two 2024 studies in Nature demonstrated that BRCA1-BARD1 directly stimulates EXO1-dependent and BLM-DNA2 or WRN-DNA2 long-range resection, while also protecting stalled replication forks from excessive nuclease degradation. The BARD1 subunit reads the H2AK15 ubiquitin mark and unmethylated H4K20 characteristic of newly replicated chromatin, which explains why the complex is preferentially recruited to breaks in the S and G2 phases of the cell cycle, when a sister chromatid is available as a template. BRCA1 also promotes the removal of 53BP1 from damage sites and accelerates CtIP-mediated resection, tipping the balance decisively toward homologous recombination precisely when the template-based pathway is feasible and safest.

The review also emphasizes an emerging layer of regulation involving RNA. Transient RNA-DNA hybrids, or R-loops, form at double-strand breaks and are required for efficient repair, yet their persistence is dangerous: accumulated hybrids interfere with resection and homologous recombination and can promote chromosomal translocations. Helicases such as senataxin, DDX5, DHX9 and the DEAD-box protein DDX1, together with RNase H enzymes recruited by BRCA2, resolve these structures at the right time. Remarkably, RNA transcripts can also stimulate repair directly: the discovery of DR-loops, three-stranded intermediates containing both DNA-DNA and RNA-DNA pairing, showed that RNA can help guide the homology search, and recent work suggests RNA transcripts may even serve as templates for repair in human cells, particularly in post-mitotic neurons where sister chromatids are unavailable.

Why does all this matter for medicine? The clearest example is PARP inhibitor therapy, built on the synthetic lethality between BRCA1 or BRCA2 deficiency and inhibition of poly(ADP-ribose) polymerase, a concept demonstrated in landmark 2005 studies and now a mainstay of treatment for BRCA-mutated breast, ovarian, pancreatic and prostate cancers. Tumors frequently escape by restoring the homologous recombination pathway without fixing the original BRCA mutation. Loss of 53BP1, or of its effectors such as RIF1, shieldin components, REV7 or the CST complex, releases the brake on resection and rescues BRCA1-deficient cells from PARP inhibitor sensitivity. Longitudinal profiling of patients has revealed that reversion mutations in BRCA1 and BRCA2 can co-occur with alterations in TP53BP1, RIF1 and PAXIP1, revealing polyclonal and mechanistically diverse routes to drug resistance within the same patient.

The pathway-choice framework also points to new therapeutic vulnerabilities. Homologous-recombination-deficient tumors depend on polymerase theta, an enzyme that mediates an alternative end-joining route, and first-in-class Pol-theta inhibitors have now entered development as potential synthetic lethal partners alongside PARP inhibitors. Conversely, understanding how the CST complex, through its subunits CTC1, STN1 and TEN1, directly blocks both EXO1 and BLM-DNA2 resection suggests that nuclease inhibition is a second, independent mechanism by which cells protect DNA ends, one that operates at telomeres and at replication-coupled breaks as well as at damage-induced double-strand breaks. Each of these nodes is a potential drug target or biomarker in its own right.

What emerges from this synthesis is a picture of repair pathway choice as a dynamic, multi-layered decision governed by cell-cycle position, chromatin state, the availability of a homologous template, the enzymatic machinery assembled at the break, and even the RNA molecules transcribed nearby. The authors caution that despite concerted efforts by many laboratories, the field is only beginning to appreciate the mechanisms that underpin the choice between homologous recombination and end joining. As those mechanisms come into focus, they are increasingly legible in the clinic: in the genetic signatures of PARP inhibitor resistance, in biomarkers such as 53BP1 expression that predict treatment response, and in the design of the next generation of therapies that exploit the repair weaknesses cancer cells cannot hide.

Subject of Research: Mechanisms governing the choice between homologous recombination and non-homologous end joining in DNA double-strand break repair and their relevance to cancer and therapeutic resistance.

Article Title: Mechanisms and disease relevance of DNA break repair pathway choice

Article References: Swift, M. L., Rogers, C. M., Kaur, H., Chowdhury, D., & Sung, P. (2026). Mechanisms and disease relevance of DNA break repair pathway choice. Nature Reviews Molecular Cell Biology. https://doi.org/10.1038/s41580-026-01026-3

Image Credits: AI Generated

DOI: 10.1038/s41580-026-01026-3

Keywords: DNA double-strand breaks, homologous recombination, non-homologous end joining, DNA end resection, BRCA1-BARD1, 53BP1, shieldin, PARP inhibitors, R-loops, genome stability, synthetic lethality, drug resistance

Checkpoint kinase 2, encoded by the CHEK2 gene, sits at a pivotal node in the DNA damage response. When breaks are detected, the master transducer ATM phosphorylates checkpoint kinase 2, which in turn propagates the alarm by phosphorylating a panel of downstream targets, including the tumor suppressor p53, the checkpoint regulator BRCA1 and the cell-cycle effector CDC25A. The result is a coordinated halt in cell division that buys time for repair, or, if the damage is beyond salvation, steers the cell toward senescence or apoptosis. Because biallelic loss-of-function mutations in CHEK2 confer a substantially elevated risk of breast cancer and other malignancies, understanding precisely what the kinase does, and what cells do without it, has occupied genome stability researchers for more than two decades.

The central question addressed in the new work is one of pathway choice. Mammalian cells deploy two principal strategies to mend double-strand breaks. Homologous recombination is the high-fidelity route: it uses the intact sister chromatid as a template and is largely restricted to the S and G2 phases of the cell cycle, when such a template exists. Non-homologous end joining, by contrast, can operate throughout the cell cycle. It directly religates broken ends, quickly but with the potential for small insertions or deletions at the junction. A third pathway, alternative end joining or microhomology-mediated end joining, relies on short exposed sequence repeats and is generally considered more error-prone still. Which pathway a cell engages for any given break has profound consequences: homologous recombination preserves the genetic message, while the end-joining routes can quietly rewrite it.

Pathway choice is not random. It is orchestrated by a molecular choreography that begins with the rapid accumulation of the MRE11-RAD50-NBS1 complex and the signaling protein 53BP1 at break sites. A tug-of-war then ensues. 53BP1, together with its effectors RIF1 and the shieldin complex, blocks the nucleolytic resection of DNA ends, thereby favoring end joining. BRCA1, in combination with PALB2 and BRCA2, promotes the removal of 53BP1 and supports the long-range resection that generates the single-stranded DNA overhangs required for homologous recombination. Cell-cycle cues, chromatin state and the availability of key enzymes all tilt this balance. Checkpoint kinase 2 has long been suspected of influencing the process, both through its well-characterized phosphorylation of BRCA1 and through its role in enforcing the cell-cycle checkpoints that determine whether a sister chromatid template is even available.

According to the study, checkpoint kinase 2 deficiency measurably affects how cells engage these repair pathways after DNA damage. Rather than a simple loss of repair capacity, the deficiency appears to shift the relative engagement of the competing routes, altering the balance between resection-dependent, template-directed repair and direct end joining. This distinction matters because a cell can maintain apparently adequate bulk repair throughput while quietly accumulating a different spectrum of errors. The work suggests that the kinase functions not merely as an amplifier of the damage signal but as a determinant of repair-pathway engagement, embedding cell-cycle and damage-load information into the repair decision itself.

The experimental logic behind such conclusions typically rests on a combination of genetic manipulation and reporter assays. Researchers induce defined double-strand breaks with site-specific nucleases or ionizing radiation, then measure the relative use of homologous recombination and end joining with engineered fluorescent or antibiotic-resistance reporters in which restoration of a disrupted gene depends on a specific repair route. Complementary biochemical readouts, including chromatin immunoprecipitation for repair factors such as RAD51, 53BP1 and RIF1, and assays of single-stranded DNA generation at break sites, reveal how the recruitment landscape changes when checkpoint kinase 2 is absent. Cell-cycle fractionation is essential, since the phases in which homologous recombination is available are exactly the phases most affected by checkpoint loss, and the new study’s emphasis on engagement rather than raw capacity points to analyses of this kind.

Why should a signaling kinase have a hand in pathway choice at all? One likely answer lies in the temporal logic of the DNA damage response. Checkpoint kinase 2 activation is among the earliest events after a break occurs, and its phosphorylation of CDC25A triggers the degradation of that phosphatase, preventing cells from entering or progressing through S phase while breaks persist. This checkpoint function is intimately tied to resection biology: productive homologous recombination requires time, a sister chromatid and a permissive cell-cycle window, all of which are guaranteed by an intact checkpoint. Without checkpoint kinase 2, cells may proceed into or through S phase with unrepaired breaks, encounter lesions without an appropriate template context, and default more heavily toward end-joining mechanisms that demand no such coordination. The kinase’s phosphorylation of BRCA1, meanwhile, has been implicated in recruiting and stabilizing the recombination machinery at damage sites, providing a second, more direct link to pathway selection.

The clinical resonance of these findings is difficult to overstate. CHEK2 is one of the most frequently mutated moderate-risk breast cancer susceptibility genes identified to date, carried by a meaningful fraction of women in population cohorts across Europe and North America. If loss of the kinase biases cells toward error-prone repair in specific contexts, that bias could help explain why CHEK2 carriers accumulate oncogenic mutations over a lifetime, and why their tumors display characteristic patterns of genomic scarring. There is also a therapeutic dimension. Inhibitors of poly(ADP-ribose) polymerase exploit the dependence of BRCA-deficient tumors on alternative repair routes, and a refined understanding of how checkpoint kinase 2 loss reshapes pathway engagement could inform whether CHEK2 mutation carriers respond differently to PARP inhibitors, radiation or certain chemotherapeutics that inflict DNA damage deliberately.

The study also speaks to a broader conceptual shift in genome biology. For many years, the DNA damage response was portrayed as a linear circuit: damage in, signal transduced, repair out. The contemporary picture is far more networked, with feedback loops, phase-specific constraints and kinetic competition among repair factors deciding the fate of each lesion. Checkpoint kinases were initially assigned narrow roles as clock-setters, pausing the cycle while repair proceeded. The accumulating evidence, including the pathway-engagement effects documented in this study, suggests instead that signaling and repair are intertwined at the level of mechanism, not merely sequence. The kinase does not simply buy time for repair; it helps determine which repair will occur.

Open questions remain. The precise phosphorylation events that link checkpoint kinase 2 to the resection machinery are still being mapped, and the extent to which the pathway-choice effects seen in cell models generalize to human tissues bearing heterozygous CHEK2 mutations, the situation in most carriers, awaits further investigation. It will also be important to determine whether the altered repair balance in checkpoint kinase 2-deficient cells produces the mutation signatures now detectable in tumor genomes, allowing epidemiologists to connect carrier status to specific patterns of somatic evolution. What the study establishes is that a deficiency in checkpoint kinase 2 changes not just the speed of the cellular response to double-strand breaks but its character, tilting the molecular tug-of-war that decides whether the genome’s severed strands are stitched back together faithfully or patched in ways that leave a permanent, and potentially dangerous, record. In the ongoing effort to understand why some inherited variants so potently predispose to cancer, that shift in repair engagement may prove to be one of the most consequential consequences of losing this guardian of the genome.

The study’s timing is notable given renewed interest in checkpoint kinases as drug targets. Selective checkpoint kinase 2 inhibitors have been explored in oncology, partly on the premise that transient checkpoint loss can sensitize tumors to DNA-damaging agents by forcing cells to divide before repair is complete. The observation that the kinase influences which repair route is engaged adds a further consideration: pharmacological inhibition might not simply accelerate breakage-driven death in cancer cells but could also reshape repair choices in exposed normal tissue, a variable worth measuring in preclinical safety work.

The findings may also intersect with tissue-specific mutation patterns seen in CHEK2 families. Unlike BRCA1 and BRCA2, which confer pronounced ovarian cancer risk, CHEK2 mutations are associated predominantly with breast cancer, with weaker or uncertain links to other tumor types. A repair-pathway explanation would predict that the consequences of losing the kinase depend on how often a given tissue relies on the routes whose engagement is altered, offering a framework for those epidemiological differences.

Methodologically, distinguishing a genuine shift in pathway engagement from a secondary consequence of checkpoint failure remains analytically demanding. Because checkpoint loss changes cell-cycle distributions, apparent differences in reporter outcomes can reflect altered timing rather than altered mechanism, making properly controlled, phase-matched comparisons essential for interpreting this and future studies of signaling kinases in repair decisions.

Subject of Research: The role of checkpoint kinase 2 in DNA double-strand break repair pathway choice

Article Title: Checkpoint kinase 2 deficiency affects the engagement of DNA double-strand break repair pathways following DNA damage

Article References: Muñoz-Maldonado, C., Etter, R., Quintin, A., Degen, P. M., Medo, M., Aebersold, D. M., Zimmer, Y., & Medová, M. (2026). Checkpoint kinase 2 deficiency affects the engagement of DNA double-strand break repair pathways following DNA damage. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03340-3

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03340-3

Keywords: checkpoint kinase 2, CHEK2, DNA double-strand breaks, homologous recombination, non-homologous end joining, DNA damage response, BRCA1, ATM, genome stability, cancer susceptibility, pathway choice, DNA repair

ATRX has occupied a special place in chromatin biology for more than two decades. Mutations in the ATRX gene cause alpha-thalassemia/mental retardation X-linked syndrome, a condition marked by severe intellectual disability, anemia, and characteristic changes in DNA methylation patterns. The protein belongs to the SWI/SNF family of ATP-dependent chromatin remodelers and carries a conserved ADD domain that reads chemical tags on histone H3, allowing ATRX to home in on specific regions of the genome. Early work established that ATRX binds highly repetitive, difficult-to-copy DNA sequences—tandem repeats, ribosomal DNA, pericentromeric heterochromatin, and telomeres—suggesting that its cellular job is to smooth out the rough patches of the genome. But precisely how ATRX accomplishes this, and which partner molecules divide the labor with it, has remained stubbornly unresolved. The new study tackles that question head-on by separating ATRX’s activities into discrete, mechanistically distinguishable functions and then testing how each one interfaces with the 9-1-1 and CST complexes.

The 9-1-1 complex, a heterotrimeric ring structurally related to the sliding clamps that tether DNA polymerases, is loaded onto recessed DNA junctions during replication stress. It functions as a platform for recruiting factors that restart stalled forks, enforce cell-cycle checkpoints, and fill in gaps left behind when the replication fork runs into trouble. The CST complex—composed of CTC1, STN1, and TEN1—was originally characterized as a helper for telomere maintenance, facilitating the synthesis of telomeric repeats by polymerase alpha-primase and protecting chromosome ends from inappropriate DNA damage responses. In recent years, however, CST has emerged as a genome-wide player: it fills in so-called C-strands at telomeres, assists with the completion of lagging-strand synthesis at difficult sites throughout the genome, and restarts replication after forks collapse. Because ATRX-deficient cells show hallmark signs of replication failure at telomeres and other repetitive regions, the possibility that ATRX and these two complexes operate in a common pathway was an obvious but untested hypothesis.

Using a combination of genetic epistasis experiments, live-cell imaging, and biochemical assays, the research team systematically perturbed ATRX, components of the 9-1-1 complex, and members of CST, then examined how these perturbations affected the cells’ ability to complete DNA synthesis at fragile genomic sites. The results reveal a layered defense architecture. One ATRX function—its capacity to remodel nucleosomes at problematic loci—acts upstream, preventing replication forks from stalling in the first place. A second, ATPase-independent function operates after fork trouble begins, cooperating with 9-1-1 to promote the resumption of DNA synthesis and the suppression of DNA damage signaling in regions that remain difficult to traverse. When either ATRX or the 9-1-1 clamp is disabled, cells accumulate under-replicated DNA and chromosome abnormalities that are characteristic of replication catastrophe, and the two defects are not additive—a genetic signature indicating that ATRX and 9-1-1 function in the same pathway rather than in parallel ones.

The telomere story is particularly striking. Telomeres terminate in single-stranded overhangs that must be filled in to form complete double-stranded DNA; failure to do so triggers chromosome-end fusions and catastrophic genome rearrangements. CST is the canonical executor of this fill-in reaction, recruiting and stimulating polymerase alpha-primase at chromosome ends. The new work shows that ATRX does not duplicate this function but rather supports it: in cells lacking ATRX, CST fails to complete its job efficiently at telomeres, leaving persistent single-stranded tails and exposing chromosome ends to aberrant repair. Restoring ATRX, or specifically rescuing its chromatin-remodeling activity at telomeric repeats, restores proper CST-dependent fill-in and eliminates the telomere dysfunction markers that otherwise accumulate. The authors present evidence that ATRX’s remodeling of the repetitive nucleosome arrays at telomeres creates a chromatin environment in which CST and the polymerase machinery can access their substrate—essentially clearing the molecular clutter that would otherwise block the repair crew.

This division of labor has significant implications for how scientists understand the genome-wide consequences of ATRX loss in human disease. ATRX syndrome patients carry mutations scattered across the protein, and previous studies had struggled to connect the dots between ATRX’s in vitro biochemical activities and the specific cellular phenotypes seen in patients. By demonstrating that distinct ATRX functions—nucleosome remodeling, checkpoint cooperation through 9-1-1, and CST-dependent telomere maintenance—can be genetically separated and mechanistically ordered, the study provides a framework for interpreting patient mutations. It suggests that different clinical presentations might correspond to different degrees of impairment in these parallel arms of ATRX function, opening the door to genotype-specific predictions about disease severity and, potentially, to therapeutic strategies that compensate for one defective arm by strengthening another.

The research also reframes a long-standing puzzle in telomere biology. Certain inherited disorders—collectively known as telomere biology disorders, including Coats plus syndrome and dyskeratosis congenita—arise from mutations in CST components themselves. The finding that ATRX acts upstream of CST in telomere maintenance suggests a functional connection between ATRX syndrome and these CST-linked diseases, even though the clinical symptoms differ. Both classes of patients show signs of shortened or dysfunctional telomeres, defective DNA replication at chromosome ends, and heightened sensitivity to replication stress. The new study provides a mechanistic bridge: it is the coordinated action of ATRX, 9-1-1, and CST that ensures telomeres are replicated and completed properly, and disruption at any point in this triad produces overlapping—but not identical—forms of genome instability.

From a broader perspective, the work speaks to one of the central organizing principles of modern genome biology: that the cell’s response to replication stress is not a single pathway but a combinatorial network, in which dedicated factors specialize in different classes of difficult DNA and in different stages of the replication process. ATRX, 9-1-1, and CST represent three nodes of this network—chromatin remodeling, fork restart, and DNA synthesis completion, respectively—and the new data show that they are not merely co-present at problematic sites but actively interdependent. Removal of any one node increases the burden on the others and, when that burden exceeds a threshold, converts a recoverable stall into an unrecoverable fork collapse. This kind of systems-level understanding is increasingly viewed as essential for predicting how cells fail under stress and how such failures propagate into disease.

The implications extend to cancer biology as well. ATRX is mutated or silenced in a substantial fraction of tumors, particularly gliomas, pancreatic neuroendocrine tumors, and certain sarcomas. These tumors frequently rely on an alternative mechanism of telomere maintenance, called alternative lengthening of telomeres or ALT, which uses homologous recombination to extend chromosome ends without the enzyme telomerase. The loss of ATRX is one of the most reliable predictors of ALT activation in clinical pathology, and the new findings provide a plausible mechanistic explanation: without ATRX to safeguard telomere replication and support CST-dependent fill-in, surviving cells are pushed toward recombination-based strategies to keep their chromosome ends intact. Understanding the precise molecular handoffs between ATRX, 9-1-1, and CST may therefore reveal vulnerabilities in ALT-positive cancers that could be exploited therapeutically, for instance by targeting the recombinational pathways that ATRX-deficient tumors depend upon.

The study, published in Nature Structural & Molecular Biology, represents a substantial step forward in resolving the functional anatomy of ATRX and situating it within the larger machinery that guards the genome during DNA replication. It replaces a broad and somewhat vague notion—ATRX protects difficult DNA—with a concrete, mechanistic model: ATRX remodels chromatin to prevent replication problems, cooperates with 9-1-1 to recover from the problems that still arise, and enables CST to complete the final steps of DNA synthesis at telomeres and other lagging-strand regions. As genome instability remains a driving force in cancer, aging, and inherited disease, dissecting these molecular partnerships is not merely an academic exercise; it is a necessary step toward interventions that can either prevent or exploit the failures of genome maintenance. The ATRX–9-1-1–CST axis now stands as one of the clearest examples of how the cell choreographs its replication machinery across the most treacherous stretches of the human genome—and of what goes wrong when that choreography breaks down.

The review, published on 26 August 2026 by Xinyan Zou, Botao Zhang, Binxian Gu, Yong Gong, Yanchao Bai and Likui Zhang, focuses on NurA as a central component of a compact DNA end-resection machine. In archaeal cells, NurA works together with the HerA helicase and the Mre11-Rad50 complex. Their combined task is to process the broken ends of DNA and generate single-stranded DNA tails with a free 3′ end. These tails are essential substrates for homologous recombination, a repair pathway that uses an intact DNA molecule as a template to restore missing genetic information.

The first challenge after a double-strand break is not simply joining the broken ends. For homologous recombination to begin, the cell must carefully reshape the damaged DNA. One strand is progressively removed from each broken end, exposing the complementary strand as single-stranded DNA. This directional process, known as end resection, creates a molecular platform on which recombination proteins can assemble. The resulting 3′ single-stranded tails are particularly important because they can search for and pair with a matching sequence in an undamaged chromosome. NurA appears to perform a major part of the enzymatic cutting required to produce these tails, while HerA helps unwind the DNA and Mre11-Rad50 contributes to the initial recognition and processing of the break.

Structurally, archaeal NurA forms a toroidal dimer, producing a ring-shaped molecular assembly with a central channel. This architecture is more than a visual feature. A ring-shaped nuclease can help confine DNA within a defined catalytic environment, positioning the nucleic acid for controlled cleavage as it passes through or interacts with the channel. The dimeric arrangement also creates an extended surface for DNA binding and may help coordinate the movement of DNA with the action of the associated HerA helicase. According to the review, NurA and HerA can form a continuous channel, suggesting that DNA may be transferred directly from the helicase into the nuclease without freely diffusing into the surrounding cell.

NurA possesses two related but distinct catalytic capabilities. It can act as a 5′-to-3′ exonuclease, removing nucleotides sequentially from a DNA end, and it can also function as an endonuclease, cutting within a DNA strand rather than only at its terminus. These activities provide the enzyme with flexibility during repair. Exonucleolytic digestion can enlarge a resected region from an existing DNA end, while endonucleolytic cleavage may help initiate processing at particular DNA structures or positions. The balance between the two activities is likely to depend on the DNA substrate, the arrangement of the protein complex and the presence of partner enzymes, although the review emphasizes that important mechanistic questions remain unresolved.

The chemical engine behind NurA’s activity is a divalent metal ion. In particular, manganese ions, or Mn²⁺, are described as essential for catalysis. Like many nucleases, NurA is thought to use metal ions to organize the DNA substrate, activate water molecules and stabilize the negatively charged reaction intermediates that form when phosphodiester bonds are broken. The requirement for Mn²⁺ highlights the importance of the enzyme’s catalytic environment: without the appropriate metal cofactor, the chemical steps needed to cleave DNA cannot proceed efficiently. The review also summarizes the identification of amino acids that contribute to DNA binding and strand cleavage, helping define how NurA recognizes its substrate and positions the scissile phosphate bond for hydrolysis.

The NurA–HerA partnership is particularly significant because it links two physically different operations: DNA unwinding and DNA degradation. HerA is a helicase that uses energy from nucleotide hydrolysis to separate the two strands of the DNA duplex. NurA, positioned alongside it, can then process the exposed strand. Their continuous channel offers a possible explanation for how archaeal cells coordinate these reactions while minimizing the risk of uncontrolled DNA degradation. Rather than allowing a nuclease and helicase to operate independently, the paired system could guide DNA through a protected molecular corridor in which unwinding and resection are synchronized. The Mre11-Rad50 complex adds another layer of coordination by participating in the detection and early processing of broken chromosome ends.

This compact repair system is also important from an evolutionary perspective. NurA homologs are found across archaeal lineages and in some bacteria, but no NurA counterpart is known in eukaryotes. At the same time, eukaryotic cells possess more elaborate DNA end-resection pathways that perform related functions through different protein assemblies. The presence of NurA in archaea, together with its partnership with HerA and Mre11-Rad50, raises questions about how ancient DNA repair strategies were reorganized during the transition from prokaryotic ancestors to the first eukaryotic cells. The review presents NurA as a potentially valuable molecular marker for tracing which parts of double-strand break repair machinery were retained, replaced or lost during evolution.

Particular attention is drawn to the Asgard superphylum, a group of archaea considered especially relevant to studies of eukaryotic origins. Genomic surveys have identified widespread, previously uncharacterized NurA homologs in Asgard archaea. These proteins could reveal whether the structural and catalytic features observed in other archaeal NurA enzymes were already present in lineages related to the ancestors of eukaryotes. However, the review makes clear that Asgard-derived NurA proteins have not yet been experimentally characterized. Their biochemical activities, metal requirements, oligomeric states and interactions with HerA or Mre11-Rad50 remain open questions. Sequence similarity alone cannot establish whether these proteins possess the same dual nuclease activities or assemble into comparable DNA-processing channels.

The authors therefore identify structural biology and biochemistry as priorities for the next stage of research. Determining the three-dimensional structures of Asgard NurA proteins, ideally in complexes with DNA, HerA and metal ions, could show whether their active sites and central channels resemble those of previously studied archaeal enzymes. Complementary experiments could measure their exonuclease and endonuclease activities, define their substrate preferences and test how mutations in DNA-binding or catalytic residues affect repair-related reactions. Reconstituting the NurA–HerA–Mre11-Rad50 system outside the cell would be especially informative because it could reveal how each component contributes to end resection and whether the proteins form a stable, coordinated machine. By connecting molecular structure with biochemical function and evolutionary distribution, NurA research may help explain how cells across the domains of life learned to repair broken chromosomes—and why some lineages ultimately replaced this ancient strategy with entirely different molecular solutions.

Subject of Research: Archaeal NurA nuclease and its role in DNA double-strand break repair

Article Title: Archaeal NurA nuclease: structure, catalytic mechanism, and functional cooperation in DNA double-strand break repair

Article References: Zou, X., Zhang, B., Gu, B. et al. “Archaeal NurA nuclease: structure, catalytic mechanism, and functional cooperation in DNA double-strand break repair.” Applied Microbiology and Biotechnology (2026). https://doi.org/10.1007/s00253-026-14009-3

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s00253-026-14009-3

Keywords: NurA nuclease; Archaea; DNA double-strand break repair; HerA helicase; Mre11-Rad50; homologous recombination; DNA end resection; Mn²⁺-dependent nuclease; Asgard archaea; molecular evolution

DNA is continuously exposed to chemical damage. Thousands of reactions occur inside every cell each day, and some of them alter DNA bases, break chemical bonds or interfere with the normal pairing of the two strands. Cells possess several repair systems that patrol the genome and correct many of these lesions. But repair is not perfect. Some damaged sites are recognized quickly and repaired efficiently, while others remain undetected long enough to be copied during cell division. Once a damaged base is converted into a different sequence through replication or faulty repair, the change may become permanent. “The rate at which mutations accumulate is a balance between the rate of damage and the rate of repair,” explains Dr. Ariel Afek, whose laboratory led the study. That balance is not uniform across the genome, and the new work helps reveal why.

Most research on genome instability has focused on mutations that are easy to observe because they remain as lasting changes in DNA. Afek’s team instead examined the temporary lesions that precede those changes. This distinction is important because a damaged DNA base does not inevitably become a mutation. Its fate depends on whether repair enzymes locate it, bind to it and remove it before the cell copies the damaged strand. To investigate these early steps, the researchers created a molecular chip containing thousands of short DNA molecules. Each molecule carried the same type of artificial damage, but the surrounding DNA letters were varied. This design allowed the scientists to compare repair activity at many sequence contexts while keeping the central lesion constant.

The experiments showed that the repair enzymes did not treat every damaged site equally. Their ability to recognize and bind the lesion depended on the precise combination of bases around it. The influence extended as far as five DNA positions upstream or downstream from the damaged base, indicating that the enzymes read a much larger molecular environment than the lesion alone. Noga Levy, a doctoral student in Afek’s laboratory and the study’s lead researcher, compared this behavior to an editor evaluating a word in context rather than in isolation. A damaged base may be chemically identical in two locations, yet the surrounding sequence can determine whether a repair protein notices it efficiently or passes it by.

The sequence effect was not simply a matter of the letters themselves. The researchers found that preferred DNA sequences shared physical characteristics, including distinctive shapes in the double helix. DNA is often represented as a uniform spiral staircase, but its structure changes subtly from one sequence to another. Some combinations of bases bend more easily, widen or narrow the grooves on the helix, or alter the distribution of electrical charge along the molecule. One of the repair enzymes studied by the team favored damaged sites embedded in sequences that create an unusually narrow region of the double helix. Such structural variation can provide a recognition signal that complements the chemical features of the damaged base.

To understand the molecular basis of this preference, the Weizmann researchers collaborated with a group led by Prof. Brian P. Weiser at Rowan University in New Jersey. Using computer simulations, the scientists examined how the repair enzyme moved across DNA and interacted with the region surrounding the lesion. The simulations indicated that one amino acid in the enzyme scans the local DNA structure. It is attracted to the negative electrical charge associated with the narrow helical region, helping guide the protein toward sequences with the appropriate shape. This model illustrates how DNA repair can depend on both chemistry and mechanics: the enzyme is not only searching for a damaged base, but also sensing the architecture and electrostatic landscape of the surrounding double helix.

The team then asked whether these biochemical preferences could be detected in the human genome after millions of years of evolution. One common form of genomic damage occurs when a cytosine, or C base, is chemically altered and no longer pairs correctly with guanine. Several important repair enzymes identify and remove the incorrect base, restoring the proper sequence. The researchers reasoned that genomic regions where a particular repair enzyme operates efficiently should preserve more cytosines, because damage at those sites would be more likely to be corrected. In regions where repair is inefficient, comparable damage should more often escape correction and accumulate as mutations. Analysis of genomic data revealed a correlation consistent with this prediction for one of the enzymes. The result suggests that repair preferences are not merely laboratory curiosities; over evolutionary time, they can influence which sequences remain stable and which become progressively altered.

That observation has implications for interpreting human evolution. When scientists identify genetic changes that became common in modern humans, they often ask whether those changes were favored because they helped people adapt to environmental pressures. But not every widespread change necessarily reflects natural selection. Some may have accumulated because the DNA sequence was especially vulnerable to damage or because repair enzymes were less effective in that context. “To identify which genomic changes were adopted by humans to survive a changing environment, we must first understand which changes accumulate naturally due to the preferences of the repair mechanisms,” Afek says. Distinguishing selection from repair-driven mutation could make evolutionary analyses more precise, particularly in genomic regions with unusually high or low mutation rates.

The same principle may help explain the genetic history of cancer. A tumor typically begins when one cell accumulates mutations that alter growth control, DNA maintenance or communication with neighboring cells. As that cell divides, additional changes form characteristic combinations known as mutational signatures. These signatures can reveal the kinds of damage that occurred and the repair pathways that were active or defective. In the new study, the researchers found a relationship between the sequence preferences of the repair enzymes and mutation patterns observed in human tumors. One explanation is that damage to repair systems in cancer cells allows mutations to accumulate in genomic regions that were previously protected. Another is that evolution has tuned repair enzymes to recognize regions that are intrinsically more vulnerable. Although the study does not establish a single cause, it reinforces the idea that repair activity is a major force shaping cancer genomes.

The findings may ultimately have practical applications beyond understanding mutation. DNA repair enzymes are already used in biotechnology and gene-editing systems, where their ability to recognize particular structures can be harnessed to modify genetic material. Mapping the sequence and shape preferences of these proteins could allow researchers to design more precise molecular tools or engineer enzymes that protect vulnerable regions of the genome more effectively. Afek’s laboratory is extending the approach to additional repair mechanisms in work led by graduate student Noga Carmon. By studying repair as a process that combines damage recognition, sequence context, molecular shape and electrical charge, scientists may gain a more complete view of how cells preserve genetic information—and how failures in that preservation can drive disease.

Web References: Nature Communications article; DOI link

References: Nature Communications, DOI: 10.1038/s41467-026-74090-0

Keywords: DNA repair, mutations, genome stability, genetic damage, structural biology, DNA sequence context, cancer genomics, mutational signatures, evolution, gene editing